Login to Your Account

Hifibio cranks up ambitions with $37.5M series B

By Michael Fitzhugh
Staff Writer

Thursday, May 17, 2018

Hifibio Therapeutics, a platform player until now, has secured an oversubscribed $37.5 million series B financing aimed at helping it build its own pipeline of antibody therapies for cancer and autoimmune disorders. Meanwhile, the company will continue to form new strategic partnerships, it said, such as earlier-established tie-ups with Pfizer Inc. and Janssen Biotech Inc.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription